<unk>  <unk>  is a blood product administered<unk> ly. It contains the pooled IgG<unk> s (antibodies extracted from the plasma of over a thousand blood donors).<unk> 's effects last between 2 weeks and 3 months. It is mainly used as treatment in three major categories:
Immune deficiencies - Immune deficiencies such as X-linked agammaglobulinemia, hypogammaglobulinemia (primary immune deficiencies), and acquired compromised immunity conditions ([secondary immune deficiencies), featuring low antibody levels.
Inflammatory and autoimmune diseases.
Acute infections.
In 2004 the FDA approved the  Cedars-Sinai<unk>  Protocol which has been 90-95% successful in removing antibodies from the blood of kidney transplant recipients so that they can accept a living donor kidney from any healthy donor no matter blood type (ABO incompatible) or tissue match.
Intravenous immunoglobulin
Pegylated interferon-alpha-2a
Pegylated interferon alpha
Anti-thymocyte globulin
Pegylated interferon alfa-2a
Pegylated interferon alfa-2b
Peginterferon Beta-1a
Interferon beta-1a